Trials / Completed
CompletedNCT00664742
The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome
The Effect Of Fluvastatin XL® Treatment On The Lipid Profile In Patients With Metabolic Syndrome
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 614 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 20 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluvastatin XL® | Fluvastatin extended release 80 mg |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2008-04-23
- Last updated
- 2011-05-17
- Results posted
- 2011-05-17
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00664742. Inclusion in this directory is not an endorsement.